Mobihealthnews.com | Molecular diagnostics company Atonarp scores $50M in Series D funding

WHAT IT DOES

Founded in 2010, Atonarp produces digital molecular diagnostic solutions for various industries, including pharmaceuticals, semiconductor manufacturing, industrial process control and life sciences. Its products run on proprietary spectroscopic technology to detect, analyse, and quantify molecular information.

According to a press release, unlike conventional diagnostic testing methods, the company utilises its own laser-based sensing and profiling technology to analyse small biological samples and produce a digital molecular snapshot "without any use of chemistry or expensive reagents".

The company is presently working to develop an in-vivo diagnostics platform. Slated for a 2022 release, the non-contact optical diagnostic platform can quantify analytes or substance in biofluids.